Publication | Open Access

Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain

NanomedicineDrug TargetingEngineeringVascular TargetingMedicineImmunologyInflamed BrainLocal First PassVascular BiologyTumor TargetingNeurologyBiomedical EngineeringCerebral Blood FlowNeuroimmunologyTumor MicroenvironmentCerebral Vascular RegulationNeuroinflammation